

Remarks

The Application address the Examiner's remarks in the order she presented them. Claims 1-10 are pending.

Terminal Disclaimer

The applicants submit herewith a terminal disclaimer to advance the prosecution of this application. They respectfully request that the Examiner withdraw the double-patenting rejection in light of it.

The §102 Rejection

The Examiner rejected claims 1-3, stating that the claims are anticipated by CA:88:190435. Claim 1 has been amended to proviso out the compound disclosed in this reference. Claims 2 and 3 depend from Claim 1. Claim 4 has been rewritten in independent form. Claims 7-9 have been amended so as to depend on newly amended Claim 4.

Conclusion

Applicants submit that the instant application is now in condition for allowance.

Respectfully submitted,



Barbara E. Kurys, Reg. No. 34,650
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2965
Telefax (908) 231-2626

Aventis Docket No. DEAV2001/0051 US NP 1